ATRA Atara Biotherapeutics, Inc. Stock Quote

ATRA [NASD]

Index	-	P/E	-	EPS (ttm)	-2.56	Insider Own	1.70%	Shs Outstand	101.60M	Perf Week	1.94%
Market Cap	356.16M	Forward P/E	-	EPS next Y	-2.46	Insider Trans	-6.74%	Shs Float	93.69M	Perf Month	27.08%
Income	-247.70M	PEG	-	EPS next Q	-0.78	Inst Own	-	Short Float	11.25%	Perf Quarter	-7.60%
Sales	71.80M	P/S	4.96	EPS this Y	12.40%	Inst Trans	0.30%	Short Ratio	4.36	Perf Half Y	-67.84%
Book/sh	2.53	P/B	1.87	EPS next Y	20.10%	ROA	-56.60%	Target Price	21.90	Perf Year	-62.11%
Cash/sh	4.41	P/C	1.08	EPS next 5Y	-	ROE	-92.40%	52W Range	2.83 - 20.04	Perf YTD	-69.92%
Dividend	-	P/FCF	-	EPS past 5Y	-5.70%	ROI	-121.70%	52W High	-77.42%	Beta	1.11
Dividend %	-	Quick Ratio	5.30	Sales past 5Y	-	Gross Margin	-	52W Low	59.89%	ATR	0.60
Employees	434	Current Ratio	5.30	Sales Q/Q	105.90%	Oper. Margin	-	RSI (14)	49.35	Volatility	12.64% 10.65%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	119.90%	Profit Margin	-	Rel Volume	0.50	Prev Close	4.74
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 08 AMC	Payout	-	Avg Volume	2.42M	Price	4.53
Recom	2.60	SMA20	15.54%	SMA50	-14.31%	SMA200	-56.48%	Volume	305,387	Change	-4.54%

Jul-20-22

Downgrade

Citigroup

Neutral → Sell

$8 → $3

Jul-13-22

Downgrade

Stifel

Buy → Hold

$16 → $5

Jul-13-22

Downgrade

JP Morgan

Overweight → Neutral

$10

May-10-22

Downgrade

Citigroup

Buy → Neutral

$15 → $8

May-13-21

Upgrade

JP Morgan

Neutral → Overweight

$23 → $29

Dec-09-20

Downgrade

Citigroup

Buy → Neutral

$20 → $27

Dec-08-20

Reiterated

H.C. Wainwright

Buy

$28 → $31

Nov-10-20

Reiterated

H.C. Wainwright

Buy

$26 → $28

Jun-30-20

Initiated

Evercore ISI

Outperform

Jun-15-20

Initiated

H.C. Wainwright

Buy

$25

Apr-23-20

Upgrade

Citigroup

Neutral → Buy

$14

Nov-08-19

Downgrade

JP Morgan

Overweight → Neutral

$43 → $22

Sep-27-19

Downgrade

Goldman

Neutral → Sell

$14 → $9

Sep-16-19

Downgrade

Jefferies

Buy → Hold

$32 → $15

Jun-04-19

Upgrade

Citigroup

Sell → Neutral

$23 → $24

May-30-19

Initiated

ROTH Capital

Buy

May-23-19

Initiated

Stifel

Buy

Jan-23-19

Initiated

Mizuho

Buy

Apr-10-18

Initiated

JP Morgan

Overweight

$56

Mar-16-18

Initiated

Guggenheim

Neutral

Aug-16-22 10:09AM	Horizon (HZNP) Inks Collaboration Deal with Q32 Bio for ADX-914 Zacks -7.49%
Aug-15-22 09:55AM	Does Atara Biotherapeutics (ATRA) Have the Potential to Rally 204% as Wall Street Analysts Expect? Zacks -8.56%
Aug-11-22 01:13PM	Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe Zacks -6.06%
Aug-09-22 03:01PM	Atara Lays Off 20% Of Its Workforce, Issues Update On Cell Therapies Benzinga +29.20%
Aug-08-22 05:35PM	Atara Biotherapeutics (ATRA) Reports Q2 Loss, Tops Revenue Estimates Zacks +5.52%
04:01PM	Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update Business Wire
Aug-04-22 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +6.62%
Aug-03-22 04:01PM	Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference Business Wire +6.73%
11:14AM	Horizon (HZNP) Q2 Earnings Miss Estimates, Revenues Rise Y/Y Zacks
Aug-02-22 09:35AM	After Plunging 65.7% in 4 Weeks, Here's Why the Trend Might Reverse for Atara Biotherapeutics (ATRA) Zacks
Aug-01-22 04:01PM	Atara Biotherapeutics to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022 Business Wire -5.94%
Jul-29-22 04:28PM	Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase Zacks
Jul-13-22 05:19PM	Peninsula biotech sheds half its value after deciding to continue multiple sclerosis study American City Business Journals -55.08%
04:44PM	Why Atara Biotherapeutics Stock Is Crashing Today Motley Fool
01:39PM	Mizuho On Atara Biotherapeutics - Distinguish Between Small Numbers And Science Failure Benzinga
08:26AM	Atara Biotherapeutics (ATRA) Moves 17% Higher: Will This Strength Last? Zacks
07:36AM	Atara Biotherapeutics Shares Are Plummeting - Read Why Benzinga
Jul-12-22 04:30PM	Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS Business Wire +17.03%
Jul-06-22 04:01PM	Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022 Business Wire
Jul-01-22 07:57PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +6.55%
Jun-10-22 07:31AM	Atara Biotherapeutics (NASDAQ:ATRA) shareholders are up 17% this past week, but still in the red over the last three years Simply Wall St. -7.94%
Jun-04-22 09:00AM	Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress Business Wire
Jun-03-22 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +6.42%
May-23-22 02:19PM	Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics Benzinga
May-20-22 06:49AM	Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara Benzinga
May-19-22 04:01PM	Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer Business Wire
May-11-22 06:14AM	Some Analysts Just Cut Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Estimates Simply Wall St. -12.13%
May-08-22 08:13AM	Earnings Beat: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts Simply Wall St.
May-06-22 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-05-22 05:25PM	Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates Zacks -6.70%
04:01PM	Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress Business Wire
May-03-22 08:55AM	10 Best Stocks to Buy Under $20 According to Jeremy Greens Redmile Group Insider Monkey
Apr-29-22 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire -5.36%
Apr-28-22 04:01PM	Atara Biotherapeutics to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022 Business Wire
Apr-27-22 09:25AM	Alkermes (ALKS) Tops Q1 Earnings and Revenue Estimates Zacks
Apr-26-22 03:01PM	Analysts Estimate Atara Biotherapeutics (ATRA) to Report a Decline in Earnings: What to Look Out for Zacks -7.82%
Apr-22-22 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Apr-08-22 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Apr-05-22 04:01PM	Atara Biotherapeutics Names Biopharmaceutical Executive Charlene Banard as Chief Technical Officer Business Wire -5.59%
Apr-04-22 04:01PM	Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm Business Wire
Mar-15-22 04:01PM	Atara Biotherapeutics to Host EBV and MS Day Business Wire
Mar-10-22 06:10AM	Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Revenues Simply Wall St.
Mar-04-22 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire -5.95%
Mar-02-22 08:00AM	Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 42nd Annual Virtual Healthcare Conference Business Wire
Feb-28-22 05:55PM	Atara Biotherapeutics (ATRA) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:05PM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress Business Wire
Feb-24-22 01:58PM	Is a Surprise Coming for Atara Biotherapeutics (ATRA) This Earnings Season? Zacks
12:03PM	The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics Zacks
Feb-23-22 12:57PM	Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & More Zacks
Feb-18-22 10:47AM	Why Atara Biotherapeutics Stock Is Sinking Today Motley Fool
10:40AM	Atara Biotherapeutics Shares Fall After Reporting Patient Death In ATA2271 Autologous CAR T Trial Benzinga
08:00AM	Atara Biotherapeutics Provides Update on ATA2271 Autologous CAR T Trial Business Wire
Feb-17-22 04:01PM	Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022 Business Wire -7.19%
Feb-07-22 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire
Jan-29-22 07:47AM	Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is up 6.2%, while insiders who purchased US$500k are up 2.0% Simply Wall St.
Jan-26-22 04:30PM	Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm Business Wire
Jan-24-22 11:13AM	New Landmark Nature Study Provides Long-Sought Mechanistic Link Between EBV and Multiple Sclerosis, Extending Findings from Recent Paper in Science That Identified EBV as the Leading Cause of Multiple Sclerosis Business Wire
Jan-10-22 08:30AM	Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-07-22 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-06-22 10:00AM	Be The Match BioTherapies® and Atara Biotherapeutics Announce Multi-Year Partnership Extension Business Wire
Jan-05-22 04:01PM	Atara Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-13-21 07:15PM	Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting Business Wire
Dec-09-21 08:00AM	Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021 Business Wire -6.91%
Dec-03-21 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire -5.11%
Nov-30-21 08:30AM	European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease Business Wire
05:24AM	10 Pharmaceutical Stocks to Buy Under $20 According to Jeremy Greens Redmile Group Insider Monkey
05:16AM	Shareholders in Atara Biotherapeutics (NASDAQ:ATRA) are in the red if they invested three years ago Simply Wall St.
Nov-08-21 04:01PM	Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences Business Wire
Nov-05-21 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire -8.65%
Nov-04-21 04:01PM	Atara Biotherapeutics, inc (ATRA) Q3 2021 Earnings Call Transcript Motley Fool +6.08%
10:35AM	How Much Upside is Left in Atara Biotherapeutics (ATRA)? Wall Street Analysts Think 48% Zacks
10:25AM	Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates Zacks
09:30AM	Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data Business Wire
07:30AM	Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress Business Wire
Oct-28-21 04:01PM	Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021 Business Wire
Oct-27-21 11:01AM	Hedge Fund Sentiment Is Stagnant On Atara Biotherapeutics Inc (ATRA) Insider Monkey
Oct-25-21 06:15AM	10 Cheap Value Stocks To Buy According To Seth Klarman Insider Monkey -5.30%
Oct-13-21 07:30AM	Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021 Business Wire -12.90%
Oct-04-21 07:30AM	Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®) Business Wire
Oct-01-21 06:14PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire
06:30AM	We're Not Very Worried About Atara Biotherapeutics' (NASDAQ:ATRA) Cash Burn Rate Simply Wall St.
Sep-29-21 03:30AM	Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021 Business Wire
Sep-27-21 08:30AM	European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD) Business Wire
Sep-20-21 11:50AM	10 Pharmaceutical Stocks to Buy Today According to Tiger Cub Billionaire Lee Ainslie Insider Monkey
Sep-03-21 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire
Sep-02-21 08:30AM	Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference Business Wire
Aug-09-21 09:30PM	Atara Biotherapeutics, inc (ATRA) Q2 2021 Earnings Call Transcript Motley Fool
05:25PM	Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:02PM	Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress Business Wire
04:01PM	Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors Business Wire
Aug-02-21 06:00PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
08:30AM	Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021 Business Wire
02:04AM	Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Could Be 37% Below Their Intrinsic Value Estimate Simply Wall St.
Jul-21-21 12:01PM	Is Atara Biotherapeutics Inc (ATRA) A Good Stock To Buy? Insider Monkey
Jul-02-21 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire
Jul-01-21 04:30PM	Atara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry Gamechangers Business Wire
Jun-18-21 01:12AM	Kristin Yarema Is The SVP & Chief Commercial Officer of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) And They Just Picked Up 165% More Shares Simply Wall St.
Jun-07-21 12:40PM	Atara Biotherapeutics Reveals Long-Term Overall Survival Data in Solid Organ-Transplant Patients Benzinga +6.68%
10:30AM	Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect Business Wire
Jun-04-21 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Touchon Pascal	President and CEO	Aug 16	Sale	5.04	14,806	74,548	457,287	Aug 18 06:24 PM
Dupont Jakob	EVP, Head of R&D	Aug 16	Sale	5.03	4,124	20,760	158,882	Aug 18 06:21 PM
Murugan Amar	SVP, GC & Secretary	Aug 16	Sale	5.03	3,430	17,269	131,198	Aug 18 06:21 PM
Koppikar Utpal	Chief Financial Officer	Aug 16	Sale	5.04	5,940	29,908	197,589	Aug 18 06:20 PM
Touchon Pascal	President and CEO	Jun 27	Sale	7.20	14,220	102,384	472,093	Jun 29 04:48 PM
Koppikar Utpal	Chief Financial Officer	Jun 08	Sale	5.63	5,853	32,952	203,529	Jun 10 04:20 PM
Murugan Amar	SVP, GC & Secretary	May 17	Sale	5.32	3,223	17,134	133,735	May 19 05:20 PM
Koppikar Utpal	Chief Financial Officer	May 17	Sale	5.32	5,582	29,675	207,592	May 19 05:16 PM
Dupont Jakob	EVP, Head of R&D	May 17	Sale	5.32	3,873	20,597	163,006	May 19 05:08 PM
Touchon Pascal	President and CEO	May 17	Sale	5.32	13,913	73,962	486,313	May 19 05:04 PM
Dupont Jakob	EVP, Head of R&D	Mar 01	Sale	9.86	2,221	21,890	166,879	Mar 03 07:02 PM
Koppikar Utpal	Chief Financial Officer	Mar 01	Sale	9.86	3,763	37,090	213,174	Mar 03 07:02 PM
Murugan Amar	SVP, GC & Secretary	Mar 01	Sale	9.86	2,577	25,400	136,958	Mar 03 07:02 PM
Touchon Pascal	President and CEO	Mar 01	Sale	9.86	8,828	87,009	500,226	Mar 03 07:02 PM
Dupont Jakob	EVP, Head of R&D	Feb 10	Option Exercise	9.58	5,000	47,900	95,594	Feb 14 05:42 PM
Dupont Jakob	EVP, Head of R&D	Feb 10	Sale	16.00	5,000	80,000	90,594	Feb 14 05:42 PM
Koppikar Utpal	Chief Financial Officer	Feb 07	Sale	14.46	2,496	36,096	155,702	Feb 09 04:35 PM
Dupont Jakob	EVP, Head of R&D	Jan 03	Option Exercise	9.58	5,000	47,900	95,594	Jan 05 04:47 PM
Dupont Jakob	EVP, Head of R&D	Jan 03	Sale	16.01	5,000	80,050	90,594	Jan 05 04:47 PM
Dupont Jakob	EVP, Head of R&D	Dec 01	Option Exercise	9.58	5,000	47,900	95,594	Dec 03 04:15 PM
Dupont Jakob	EVP, Head of R&D	Dec 01	Sale	17.94	5,000	89,688	90,594	Dec 03 04:15 PM
Newell Joe	Chief Operations Officer	Nov 16	Sale	17.12	3,332	57,034	113,097	Nov 18 05:54 PM
Touchon Pascal	President and CEO	Nov 16	Sale	17.12	8,402	143,816	328,489	Nov 18 05:55 PM
Murugan Amar	SVP, GC & Secretary	Nov 16	Sale	17.12	2,124	36,356	87,540	Nov 18 05:53 PM
Dupont Jakob	EVP, Head of R&D	Nov 16	Sale	17.12	2,199	37,640	90,594	Nov 18 05:52 PM
Koppikar Utpal	Chief Financial Officer	Nov 16	Sale	17.12	3,655	62,562	157,714	Nov 18 05:53 PM
Newell Joe	Chief Operations Officer	Nov 15	Option Exercise	12.15	3,500	42,525	123,429	Nov 17 04:15 PM
Newell Joe	Chief Operations Officer	Nov 15	Sale	17.71	7,000	124,004	116,429	Nov 17 04:15 PM
Fust Matthew K	Director	Nov 04	Sale	19.50	13,354	260,403	31,500	Nov 05 04:28 PM
Dupont Jakob	EVP, Head of R&D	Nov 02	Option Exercise	9.58	5,000	47,900	97,793	Nov 04 04:10 PM
Dupont Jakob	EVP, Head of R&D	Nov 02	Sale	16.41	5,000	82,050	92,793	Nov 04 04:10 PM
Newell Joe	Chief Operations Officer	Sep 22	Option Exercise	12.15	10,500	127,575	130,429	Sep 24 05:35 PM
Newell Joe	Chief Operations Officer	Sep 22	Sale	17.00	10,500	178,500	119,929	Sep 24 05:35 PM
Newell Joe	Chief Operations Officer	Sep 15	Sale	15.61	3,116	48,647	119,929	Sep 17 04:36 PM
Newell Joe	Chief Operations Officer	Aug 30	Sale	15.00	3,500	52,500	123,045	Aug 31 05:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience